Lava Therapeutics B.V. Revenue and Competitors

Claim your profile

Utrecht,

Location

$102.9M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Lava Therapeutics B.V.'s estimated annual revenue is currently $5.4M per year.(i)
  • Lava Therapeutics B.V.'s estimated revenue per employee is $70,658
  • Lava Therapeutics B.V.'s total funding is $102.9M.
  • Lava Therapeutics B.V.'s current valuation is $128.9M. (January 2022)

Employee Data

  • Lava Therapeutics B.V. has 76 Employees.(i)
  • Lava Therapeutics B.V. grew their employee count by 29% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$13.8M8922%N/AN/A
#2
$156.1M505-5%$145MN/A
#3
$4.8M62-35%$150MN/A
#4
$30.4M15725%$180.7MN/A
#5
$5.7M37-3%N/AN/A
#6
$256.3M69726%$168.5MN/A
#7
$4.8M31-22%N/AN/A
#8
$10.4M6740%N/AN/A
#9
$13.2M85-4%N/AN/A
#10
$29.5M19019%N/AN/A

At LAVA, we are focused on applying our expertise in gamma-delta T-cell engagers (TCEs) to transform cancer therapy. We refer to our compounds as gamma-delta bispecific T-cell engagers, or gamma-delta bsTCEs. Our platform generates therapeutics that specifically activate a unique and relatively abundant effector gamma-delta T-cell subset called Vγ9Vδ2 (Vgamma9-Vdelta2) T-cells that have the ability to trigger activity of immune cells of both the innate and adaptive immune system. Our gamma-delta bsTCEs have demonstrated superior efficacy and safety profiles compared to other bsTCE approaches in preclinical studies and show preferential activity against tumor cells thereby potentially limiting toxicity in healthy tissue. To date, we are the only company developing bispecific gamma-delta T-cell engaging antibodies for the treatment of cancer. We are building a pipeline of gamma-delta bsTCEs that have applications in both solid and hematologic malignancies. Our lead program, LAVA-051, targets the tumor specific antigen CD1d, which can be overexpressed in multiple myeloma, chronic lymphocytic leukemia (CLL), and acute myeloid leukemia (AML), among other tumor types. LAVA-051 will enter a Phase I/IIa study in 1Q21.

keywords:N/A

$102.9M

Total Funding

76

Number of Employees

$5.4M

Revenue (est)

29%

Employee Growth %

$128.9M

Valuation

N/A

Accelerator

Lava Therapeutics B.V. News

2022-04-17 - Research Analysts' Upgrades for April 23rd (ASX, BGFV, LIQT ...

LAVA Therapeutics B.V. is based in UTRECHT, The Netherlands. “ Lynas Rare Earths (OTCMKTS:LYSDY) was upgraded by analysts at Zacks Investment...

2022-04-17 - LAVA Therapeutics (NASDAQ:LVTX) Upgraded to Hold at ...

It focuses on applying its expertise in bispecific gamma-delta T cell engagers to transform cancer therapy. LAVA Therapeutics B.V. is based in...

2021-03-10 - LAVA Therapeutics B.V. to Present Preclinical Findings Supporting Anti-Tumor Activity of Lead Clinical Candidate LAVA-051 at the American Association for Cancer Research (AACR) Virtual 2021 Annual Meeting

UTRECHT, The Netherlands & PHILADELPHIA--(BUSINESS WIRE)--Mar 10, 2021-- LAVA Therapeutics B.V., a biotechnology company focused on applying its expertise in bispecific gamma-delta T cell engagers (bsTCE) to transform cancer therapy, today announced that a poster featuring lead clinical candida ...

2020-09-18 - Biotech startup Lava Therapeutics lands $83M

Lava Therapeutics, a Dutch developer of therapies to treat cancer, has secured an $83 million Series C investment. Novo Ventures and Sanofi Ventures led the round, which will go toward developing the startup's pipeline and fund clinical trials. As part of the deal, Novo partner Nanna Lüneborg wi ...

2020-09-17 - LAVA Therapeutics Raises $83 million in Series C

UTRECHT, The Netherlands & PHILADELPHIA--(BUSINESS WIRE)--LAVA Therapeutics, a biotech company pioneering the development of bispecific antibodies to engage gamma-delta T cells for cancer therapies, today announced the closing of an oversubscribed $83 million (€71 million) Series C financing to ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$7.5M7638%N/A
#2
$15M7724%N/A
#3
$17.8M8113%N/A
#4
N/A8547%N/A
#5
$15M8621%N/A